18. Spinocerebellar degeneration Clinical trials / Disease details
Clinical trials : 71 / Drugs : 99 - (DrugBank : 30) / Drug target genes : 45 - Drug target pathways : 65
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01970098 (ClinicalTrials.gov) | October 9, 2013 | 22/10/2013 | A Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | A Phase III Confirmatory Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose;Drug: Placebo | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | All | 374 | Phase 3 | Japan |
| 2 | NCT01970137 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | A 24-week Open-label Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | Phase 3 | Japan | ||
| 3 | NCT01970124 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | A Long-Term Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | Phase 3 | Japan | ||
| 4 | NCT01970111 (ClinicalTrials.gov) | October 2013 | 22/10/2013 | An Extension Study of KPS-0373 in Patients With Spinocerebellar Degeneration (SCD) | Spinocerebellar Degeneration | Drug: KPS-0373, High dose;Drug: KPS-0373, Low dose | Kissei Pharmaceutical Co., Ltd. | NULL | Completed | 20 Years | N/A | Both | Phase 3 | Japan |